Michael Mano - 28 Feb 2023 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
SVP, General Counsel&Secretary
Signature
/s/Nancy Smith as Attorney-in-Fact for Michael Mano
Issuer symbol
KPTI
Transactions as of
28 Feb 2023
Net transactions value
-$20,835
Form type
4
Filing time
02 Mar 2023, 16:35:19 UTC
Previous filing
01 Sep 2022
Next filing
05 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +70,000 +84% $0.000000 153,000 28 Feb 2023 Direct F1
transaction KPTI Common Stock Sale $20,835 -6,878 -4.5% $3.03 146,122 01 Mar 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.
F2 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.